Cancer Family
Leukemia
CI-CAN-00000215Explore in graph →
HematologicTop-level1,769 active trials42 approved drugs708 evidence items
Loading cancer entity…
Loading cancer entity…
Cancer Family
CI-CAN-00000215Explore in graph →
Clinical trials
8,439 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
Computedformula ci-trial-intel-v1 · interventional studies · entity + NCIt descendants · hover a figure for its formulaCompare cancersTerminated studies (1,350)
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT03642236 | Combination of BTK Inhibitor Overcomes Drug-resistance in Refractory/Relapsed FLT3 Mutant AML | unknown | Phase 2 / Phase 3 | 122 | Nanfang Hospital, Southern Medical UniversityOTHER | 1 | Aug 22, 2018 | clinicaltrials |
| NCT02333838 | Reduced Toxicity Conditioning Prior to Unrelated Cord Cell Transplantation for High Risk Myeloid Malignancies(TBF-Cord) | unknown | Phase 2 | 31 | Assistance Publique - Hôpitaux de ParisOTHER | 1 |
| Aug 13, 2018 |
| clinicaltrials |
| NCT03624686 | Production of Clinical-grade Anti-CD19 Chimeric Antigen Receptor T Cells for Refractory B-cell Malignancies | unknown | — | 130 | National Taiwan University HospitalOTHER | 1 | Aug 10, 2018 | clinicaltrials |
| NCT03625583 | The Hong Kong CML Registry | unknown | — | 200 | The University of Hong KongOTHER | 1 | Aug 10, 2018 | clinicaltrials |
| NCT02164903 | LEONIDAS: Quality of Life Study in Chronic Myeloid Leukemia Patients(QoL-CML0713) | unknown | — | 323 | Gruppo Italiano Malattie EMatologiche dell'AdultoOTHER | 4 | Aug 6, 2018 | clinicaltrials |
| NCT03613428 | Ruxolitinib Plus LVP in Patients With R/R ETP-ALL | unknown | Phase 1 / Phase 2 | 12 | Sichuan UniversityOTHER | 0 | Aug 3, 2018 | clinicaltrials |
| NCT02888977 | Tyrosine Kinase Inhibitors and Low Intensity Chemotherapy in Ph+ ALL(EWALL_OBS) | unknown | — | 100 | Versailles HospitalOTHER | 1 | Jul 30, 2018 | clinicaltrials |
| NCT02897245 | A Study for Tyrosine Kinase Inhibitors Discontinuation(A-STIM) | unknown | — | 200 | Versailles HospitalOTHER | 1 | Jul 30, 2018 | clinicaltrials |
| NCT03599869 | Management of Mixed-Phenotype Acute Leukemia in the East of France(ELABEST) | unknown | — | 70 | Central Hospital, Nancy, FranceOTHER | 0 | Jul 26, 2018 | clinicaltrials |
| NCT01429610 | Rituximab+mVPDL for CD20(+) Adult Acute Lymphoblastic Leukemia(RADICAL) | unknown | Phase 2 | 78 | Asan Medical CenterOTHER | 1 | Jul 24, 2018 | clinicaltrials |
| NCT03336632 | Chidamide Plus PTCy/Cyclosporine to Prevent GVHD After Myeloablative Conditioning, Matched PBSCT | unknown | Phase 2 | 50 | Sichuan UniversityOTHER | 1 | Jul 18, 2018 | clinicaltrials |
| NCT03586401 | Creating a Decision Support System for the Corporate Management of Physical Therapy | unknown | — | 1,000 | Federal Research Institute of Pediatric Hematology, Oncology and ImmunologyOTHER | 1 | Jul 13, 2018 | clinicaltrials |
| NCT03582241 | NGS in AML Relapse(NGSAML) | unknown | — | 40 | University Hospital, Strasbourg, FranceOTHER | 1 | Jul 12, 2018 | clinicaltrials |
| NCT03583294 | A Study on the Uterus, Ovarian and Reproductive Functions According to Conditioning Regimen and Pubertal Status at the Time of Stem Cell Transplantation in a Leukemia Pediatric Population(FERTILEA) | unknown | N/A | 212 | Assistance Publique Hopitaux De MarseilleOTHER | 1 | Jul 12, 2018 | clinicaltrials |
| NCT03578718 | Evaluation of the Interest of a Specialist in Dermatology for Dermatopediatric Consultations(HLSkinPed) | unknown | — | 100 | Central Hospital, Nancy, FranceOTHER | 0 | Jul 6, 2018 | clinicaltrials |
| NCT03564977 | CD19-targeted CAR-T Cell Therapy for MRD+ B-cell Malignancies After Autologous Stem Cell Transplantation | unknown | N/A | 20 | Qingdao Central HospitalOTHER | 1 | Jul 2, 2018 | clinicaltrials |
| NCT03573596 | Persistence of MR3 in Chronic Myeloid Leukemia (CML) After a 2nd Stop of TKI Treatment(DASTOP2) | unknown | Phase 2 | 134 | Amsterdam UMC, location VUmcOTHER | 7 | Jun 29, 2018 | clinicaltrials |
| NCT03574168 | CD19-CAR-T Cells in Patients With R/R B-ALL | unknown | Phase 1 | 40 | Bioceltech Therapeutics, Ltd.INDUSTRY | 1 | Jun 29, 2018 | clinicaltrials |
| NCT03235973 | Cladribine Dose Escalation in Conditioning Regimen Prior to Allo-HSCT for Refractory Acute Leukemia and Myelodysplastic Syndromes(CEREAL) | unknown | Phase 1 | 29 | Institut Paoli-CalmettesOTHER | 1 | Jun 28, 2018 | clinicaltrials |
| NCT03564704 | Precision Diagnosis Directing HDACi Chidamide Target Therapy for Adult T-LBL/ALL | unknown | Phase 2 / Phase 3 | 80 | Nanfang Hospital, Southern Medical UniversityOTHER | 1 | Jun 21, 2018 | clinicaltrials |
| NCT03556748 | WB-EMS and Nutrition in Patients With Hematological Malignancies | unknown | N/A | 40 | University of Erlangen-Nürnberg Medical SchoolOTHER | 1 | Jun 14, 2018 | clinicaltrials |
| NCT03556982 | CART-123 FOR Relapsed/Refractory Acute Myelocytic Leukemia（AML） | unknown | Phase 1 / Phase 2 | 10 | The Affiliated Hospital of the Chinese Academy of Military Medical SciencesOTHER | 1 | Jun 14, 2018 | clinicaltrials |
| NCT03553238 | Precision Diagnosis Directing HDACi Chidamide Target Therapy for Adult ETP-ALL | unknown | Phase 2 / Phase 3 | 70 | Nanfang Hospital, Southern Medical UniversityOTHER | 1 | Jun 12, 2018 | clinicaltrials |
| NCT03131986 | Cessation of Tyrosine Kinase Inhibitors in Patients With Chronic-phase Chronic Myelogenous Leukaemia | unknown | — | 30 | The University of Hong KongOTHER | 1 | Jun 11, 2018 | clinicaltrials |
| NCT02185261 | Interferon α for the Therapy of Minimal Residual Disease | unknown | N/A | 81 | Peking University People's HospitalOTHER | 1 | Jun 7, 2018 | clinicaltrials |
| NCT02576301 | Dose Escalation of OXi4503 as Single Agent and Combination With Cytarabine w/Subsequent Ph 2 Cohorts for AML and MDS(AML) | unknown | Phase 1 / Phase 2 | 105 | Mateon TherapeuticsINDUSTRY | 1 | Jun 4, 2018 | clinicaltrials |
| NCT03544021 | CART-19 FOR Relapsed/Refractory Acute Lymphoblastic Leukemia （ALL） | unknown | Phase 1 / Phase 2 | 10 | The Affiliated Hospital of the Chinese Academy of Military Medical SciencesOTHER | 1 | Jun 4, 2018 | clinicaltrials |
| NCT03515018 | Evaluation of the Therapeutic Effect of HU Pulse Therapy for CML Patients(HU) | unknown | Phase 3 | 60 | First Affiliated Hospital of Harbin Medical UniversityOTHER | 1 | May 22, 2018 | clinicaltrials |
| NCT02451774 | Pentoxifylline In Pediatric Acute Lymphoblastic Leukemia During Induction(PTX-II) | unknown | Phase 2 / Phase 3 | 44 | Ramón Óscar González-Ramella, Ph.DOTHER | 1 | May 9, 2018 | clinicaltrials |
| NCT03142646 | Safety and Efficacy Evaluation of IM19 CAR-T Cells(IM19CAR-T) | unknown | Phase 1 / Phase 2 | 60 | Beijing Immunochina Medical Science & Technology Co., Ltd.INDUSTRY | 1 | May 1, 2018 | clinicaltrials |
| NCT02991066 | Role of Microparticles in the Coagulopathy of Acute Promyelocytic Leukemia | unknown | — | 20 | First Affiliated Hospital of Harbin Medical UniversityOTHER | 1 | Apr 24, 2018 | clinicaltrials |
| NCT01906671 | Study on Two Different Formulations of 6-mercaptopurine. Tablet Versus Oral Liquid | unknown | Phase 4 | 16 | Kjeld SchmiegelowOTHER | 1 | Apr 20, 2018 | clinicaltrials |
| NCT03499912 | Screening of IDH1 and IDH2 Gene Mutations in Adult Acute Myeloid Leukemia for Possible Targeted Therapy | unknown | — | 300 | National Taiwan University HospitalOTHER | 1 | Apr 20, 2018 | clinicaltrials |
| NCT02991638 | Efficacy and Safety of Ibrutinib in Patients With CLL and Other Indolent B-cell Lymphomas Who Are Chronic Hepatitis B Virus Carriers or Occult Hepatitis B Virus Carriers | unknown | Phase 3 | 62 | The University of Hong KongOTHER | 1 | Apr 12, 2018 | clinicaltrials |
| NCT03495492 | Chronic Lymphocytic Leukemia Responds to Dermal Chelation | unknown | N/A | 50 | Optimum Health, Natural Healthcare CenterOTHER | 0 | Apr 12, 2018 | clinicaltrials |
| NCT03494998 | Refining and Testing the Diagnostic Accuracy of PAT-POPS | unknown | — | 80,000 | Pennine Acute Hospitals NHS TrustOTHER | 1 | Apr 11, 2018 | clinicaltrials |
| NCT03239886 | Imatinib Discontinuation in Patients With Chronic Myeloid Leukemia Chronic Phase With Sustained MR4log | unknown | N/A | 30 | University of Sao Paulo General HospitalOTHER | 1 | Mar 23, 2018 | clinicaltrials |
| NCT01862445 | Retrospective Study: Efficacy and Safety of Chlorambucil + Rituximab in CLL Patients | unknown | — | 100 | Gruppo Italiano Malattie EMatologiche dell'AdultoOTHER | 1 | Mar 22, 2018 | clinicaltrials |
| NCT02744768 | D-ALBA Frontline Sequential Dasatinib and Blinatumomab in Adult Philadelphia Positive Acute Lymphoblastic Leukemia | unknown | Phase 2 | 60 | Gruppo Italiano Malattie EMatologiche dell'AdultoOTHER | 1 | Mar 22, 2018 | clinicaltrials |
| NCT01451268 | Phase I/II Study With Oral Panobinostat Maintenance Therapy Following Allogeneic Stem Cell Transplantation in Patients With High Risk Myelodysplastic Syndrome (MDS) or Acute Myeloid Leukemia (AML)(PANOBEST) | unknown | Phase 1 / Phase 2 | 62 | Johann Wolfgang Goethe University HospitalOTHER | 1 | Mar 20, 2018 | clinicaltrials |
| NCT03462095 | De-escalated Treatment Approach for Adult Ph-negative Acute Lymphoblastic Leukemia (ALL) | unknown | N/A | 350 | National Research Center for Hematology, RussiaNETWORK | 1 | Mar 13, 2018 | clinicaltrials |
| NCT03463928 | A Feasibility and Safety Study of Concomitant Therapy With Allo-CAR-T Cells and Allo-HSCT in Patients With Relapse or Refractory Leukemia | unknown | Phase 1 | 10 | Chinese PLA General HospitalOTHER | 1 | Mar 13, 2018 | clinicaltrials |
| NCT02682732 | Molecular Imaging to Capture Disease Heterogeneity in Acute Myeloid Leukemia | unknown | N/A | 10 | Hamilton Health Sciences CorporationOTHER | 1 | Feb 22, 2018 | clinicaltrials |
| NCT03417414 | Does CMV Induced Changes in NK Lymphocyte Biology Influence the Effectiveness of Antibody Therapy Used to Treat B Cell Lymphoproliferative Diseases? | unknown | — | 160 | Ottawa Hospital Research InstituteOTHER | 0 | Feb 7, 2018 | clinicaltrials |
| NCT03419494 | Comparison of Liposomal Doxorubicin and Daunorubicin-containing VDCLD Regimen in the Treatment of Adult ALL Patients | unknown | — | 40 | CSPC ZhongQi Pharmaceutical Technology Co., Ltd.INDUSTRY | 1 | Feb 5, 2018 | clinicaltrials |
| NCT03413046 | The Effect of Chemotherapy on Regulatory T Cells | unknown | — | 60 | Ankara Children's Health and Diseases Hematology and Oncology Training and Research HospitalOTHER_GOV | 0 | Jan 29, 2018 | clinicaltrials |
| NCT03287128 | Retrospective Analysis of the Outcome of Patients With Relapsed/Refractory Acute Myeloid Leukemia Included in a Patient Named Program of Gemtuzumab Ozogamicin/Mylotarg®(MYLOR) | unknown | — | 300 | Versailles HospitalOTHER | 1 | Jan 24, 2018 | clinicaltrials |
| NCT03408210 | Total Marrow and Lymphoid Irradiation and Chemotherapy for Myelodysplastic Syndrome or Acute Leukemia | unknown | N/A | 191 | Affiliated Hospital to Academy of Military Medical SciencesOTHER | 1 | Jan 23, 2018 | clinicaltrials |
| NCT03408223 | Total Marrow and Lymphoid Irradiation and Chemotherapy for High-Risk Acute Leukemia | unknown | N/A | 100 | Affiliated Hospital to Academy of Military Medical SciencesOTHER | 1 | Jan 23, 2018 | clinicaltrials |
| NCT03398967 | A Feasibility and Safety Study of Universal Dual Specificity CD19 and CD20 or CD22 CAR-T Cell Immunotherapy for Relapsed or Refractory Leukemia and Lymphoma | unknown | Phase 1 / Phase 2 | 80 | Chinese PLA General HospitalOTHER | 1 | Jan 16, 2018 | clinicaltrials |
Data updated 24 days agoSource updated Aug 22, 2018source: clinicaltrials